Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression.

Trial Profile

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2012

At a glance

  • Drugs Antiretrovirals; Raltegravir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms INTEGRAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Sep 2011 Results at 48 weeks published in Antiviral Therapy.
    • 19 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top